ABVC BioPharma Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $296K0.0% YoYTTM through 30 Sep 2025
Net Income -$7.1MTTM through 30 Jun 2026
Free Cash Flow -$2.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -2,201.1% |
| Net Margin | -2,400.9% |
Returns
-87.8%ROE
-43.7%ROA
Balance Sheet Health
Debt / Equity0.21x
Current Ratio0.12x
Net Debt$685.5K
Cash & Equivalents$31.9K
Quality Metrics
Altman Z-Score-4.53
Piotroski F-Score3 / 9
FCF Margin-909.1%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $296K
Diluted EPS-$0.29TTMFY2025: $-0.39
Dividend
No dividend
Capital Allocation
R&D Spend$114.8K
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.